Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation — SIA-CSH

Malignant Hemopathy Clinical Trial

Official title:
Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

Status Recruiting

Clinical Trial Summary

Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Clinical Trial Description

a more in-depth analysis of the different immune cell sub-populations as well as serum markers (cytokines) would provide a better understanding of post-allograft immune reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or relapse. ;

Study Design

Related Conditions & MeSH terms

Malignant Hemopathy

Clinical Trial Details

NCT number	NCT03965429
Study type	Observational
Source	Institut Paoli-Calmettes
Contact	Dominique Genre, MD
Phone	0491223778
Email	drci.up@ipc.unicancer.fr
Status	Recruiting
Phase
Start date	May 14, 2019
Completion date	May 31, 2029

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01574235` - Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents	N/A
Recruiting	`NCT04517656` - Biomarkers Impact Evaluation on the Post-transplant Immune Response After Allografting of Hematopoietic Stem Cells	N/A
Terminated	`NCT02999152` - Validation of Radio-induced Damage Biomarkers	N/A
Terminated	`NCT00190463` - Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia	Phase 4
Active, not recruiting	`NCT04390126` - COVID-19 Related Lockdown Effects On Chronic Diseases